Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aligos Therapeutics, Inc.ALGS · Entity 7352 | See Remarks | March 09, 2026 | March 11, 2026 |
| Global Blood Therapeutics, Inc.GBT · Entity 123220 | See Remarks | May 26, 2020 | May 28, 2020 |
| Tango Therapeutics, Inc.TNGX · Entity 1497 | Director | June 05, 2026 | June 08, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aligos Therapeutics, Inc.
Report date March 09, 2026 · Filed March 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.03 · Expires 2036-03-09 | Direct | 37,485 |
Reported balance
After 2026-03-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-03-09 · Grant · Acquired 37,485 · Balance 37,485 F1: 1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from March 9, 2026 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: 1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from March 9, 2026 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.
Global Blood Therapeutics, Inc.
Report date May 26, 2020 · Filed May 28, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 154 |
Ending reported balance
After 2020-05-26 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2020-05-26 · Exercise / conversion · Acquired 2,700 · Balance 2,854 Row 2 · 2020-05-26 · Sale · Disposed 2,700 · Balance 154 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $29.75 · Expires 2027-02-28 | Direct | 900 |
Reported balance
After 2020-05-26 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-05-26 · Exercise / conversion · Disposed 2,700 · Balance 900 F1: The Stock Option becomes exercisable in sixteen equal quarterly installments after March 1, 2017 until fully vested on March 1, 2021, subject to the Reporting Person's continuous service with the Issuer. The Stock Option is subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: The Stock Option becomes exercisable in sixteen equal quarterly installments after March 1, 2017 until fully vested on March 1, 2021, subject to the Reporting Person's continuous service with the Issuer. The Stock Option is subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer.
Tango Therapeutics, Inc.
Report date June 05, 2026 · Filed June 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 16,500 |
Reported balance
After 2026-06-05 transaction · row 1
1 source rowRow 1 · 2026-06-05 · Grant · Acquired 4,000 · Balance 16,500 F1: These shares are represented by restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest in their entirety on the earlier of: (i) June 5, 2027 and (ii) the date of the next annual meeting of stockholders, in each case subject to the Reporting Person's continuous service with the Issuer as of each such vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.22 · Expires 2036-06-05 | Direct | 25,000 |
Reported balance
After 2026-06-05 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-05 · Grant · Acquired 25,000 · Balance 25,000 F2: This option shall vest and become exercisable in 12 substantially equal monthly installments over a period of one year, with the first vesting date on July 5, 2026, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares are represented by restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest in their entirety on the earlier of: (i) June 5, 2027 and (ii) the date of the next annual meeting of stockholders, in each case subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.
F2: This option shall vest and become exercisable in 12 substantially equal monthly installments over a period of one year, with the first vesting date on July 5, 2026, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 05, 2026 Filed Jun 8, 2026 22:01 UTC | Tango Therapeutics, Inc. TNGX · Entity 1497 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $20.22 | $0.00 |
DisclosureSEC source: 0001193125-26-262205 · ownership.xml · derivative · entry 2 Calhoun Lesley Ann · CIK 0001730866 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2036-06-05 F2 · derivative.exercise_date: This option shall vest and become exercisable in 12 substantially equal monthly installments over a period of one year, with the first vesting date on July 5, 2026, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date. Read SEC document |
| June 05, 2026 Filed Jun 8, 2026 22:01 UTC | Tango Therapeutics, Inc. TNGX · Entity 1497 | GrantCommon Stock | 4,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-262205 · ownership.xml · nonDerivative · entry 1 Calhoun Lesley Ann · CIK 0001730866 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,500 F1 · shares: These shares are represented by restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest in their entirety on the earlier of: (i) June 5, 2027 and (ii) the date of the next annual meeting of stockholders, in each case subject to the Reporting Person's continuous service with the Issuer as of each such vesting date. Read SEC document |
| March 09, 2026 Filed Mar 11, 2026 20:13 UTC | Aligos Therapeutics, Inc. ALGS · Entity 7352 | GrantStock Option (Right to Buy) · Derivative | 37,485 | $0.00 Strike: $7.03 | $0.00 |
DisclosureSEC source: 0001610717-26-000093 · form4.xml · derivative · entry 1 Calhoun Lesley Ann · CIK 0001730866 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,485 Underlying: Common Stock · 37,485 shares Expires 2036-03-09 F1 · derivative.exercise_date: 1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from March 9, 2026 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| July 16, 2025 Filed Jul 18, 2025 20:41 UTC | Aligos Therapeutics, Inc. ALGS · Entity 7352 | GrantStock Option (Right to Buy) · Derivative | 40,185 | $0.00 Strike: $8.68 | $0.00 |
DisclosureSEC source: 0001610717-25-000286 · form4.xml · derivative · entry 1 Calhoun Lesley Ann · CIK 0001730866 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,185 Underlying: Common Stock · 40,185 shares Expires 2035-07-16 F1 · derivative.exercise_date: 1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from July 16, 2025 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| June 05, 2025 Filed Jun 9, 2025 21:50 UTC | Tango Therapeutics, Inc. TNGX · Entity 1497 | GrantStock Option (Right to Buy) · Derivative | 37,500 | $0.00 Strike: $3.51 | $0.00 |
DisclosureSEC source: 0000950170-25-083911 · ownership.xml · derivative · entry 2 Calhoun Lesley Ann · CIK 0001730866 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,500 Underlying: Common Stock · 37,500 shares Expires 2035-06-05 F2 · derivative.exercise_date: This option shall vest and become exercisable in 12 substantially equal monthly installments over a period of one year, with the first vesting date on July 5, 2025, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date. Read SEC document |
| June 05, 2025 Filed Jun 9, 2025 21:50 UTC | Tango Therapeutics, Inc. TNGX · Entity 1497 | GrantCommon Stock | 6,250 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-083911 · ownership.xml · nonDerivative · entry 1 Calhoun Lesley Ann · CIK 0001730866 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,500 F1 · shares: These shares are represented by restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest in its entirety on the earlier of: (i) June 5, 2026 and (ii) the date of the next annual meeting of stockholders, in each case subject to the Reporting Person's continuous service with the Issuer as of each such vesting date. Read SEC document |
| February 28, 2025 Filed Mar 4, 2025 21:32 UTC | Aligos Therapeutics, Inc. ALGS · Entity 7352 | GrantStock Option (Right to Buy) · Derivative | 47,271 | $0.00 Strike: $16.87 | $0.00 |
DisclosureSEC source: 0001610717-25-000044 · form4.xml · derivative · entry 1 Calhoun Lesley Ann · CIK 0001730866 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,271 Underlying: Common Stock · 47,271 shares Expires 2035-02-28 F1 · derivative.exercise_date: 1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from February 28, 2025 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| September 04, 2024 Filed Sep 6, 2024 20:23 UTC | Aligos Therapeutics, Inc. ALGS · Entity 7352 | GrantStock Option (Right to Buy) · Derivative | 10,880 | $0.00 Strike: $11.74 | $0.00 |
DisclosureSEC source: 0001610717-24-000466 · form4.xml · derivative · entry 1 Calhoun Lesley Ann · CIK 0001730866 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,880 Underlying: Common Stock · 10,880 shares Expires 2034-09-04 F1 · derivative.exercise_date: 1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from September 4, 2024 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| June 05, 2024 Filed Jun 7, 2024 21:16 UTC | Tango Therapeutics, Inc. TNGX · Entity 1497 | GrantStock Option (Right to Buy) · Derivative | 37,500 | $0.00 Strike: $7.41 | $0.00 |
DisclosureSEC source: 0000950170-24-070875 · ownership.xml · derivative · entry 3 Calhoun Lesley Ann · CIK 0001730866 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 37,500 Underlying: Common Stock · 37,500 shares Expires 2034-06-05 F4 · derivative.exercise_date: This option shall vest and become exercisable in 12 substantially equal monthly installments over a period of one year beginning on July 5, 2024, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date. Read SEC document |
| June 05, 2024 Filed Jun 7, 2024 21:16 UTC | Tango Therapeutics, Inc. TNGX · Entity 1497 | SaleCommon Stock | 5,000 | $7.21 | $36,039.00 |
DisclosureSEC source: 0000950170-24-070875 · ownership.xml · nonDerivative · entry 2 Calhoun Lesley Ann · CIK 0001730866 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,250 F2 · kind: The reported sale occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 6, 2023. F3 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $7.01 to $7.38 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| June 05, 2024 Filed Jun 7, 2024 21:16 UTC | Tango Therapeutics, Inc. TNGX · Entity 1497 | GrantCommon Stock | 6,250 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-070875 · ownership.xml · nonDerivative · entry 1 Calhoun Lesley Ann · CIK 0001730866 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,250 F1 · shares: These shares are represented by restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest in its entirety on the earlier of: (i) June 5, 2025 and (iii) the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date. Read SEC document |
| March 01, 2024 Filed Mar 4, 2024 22:42 UTC | Aligos Therapeutics, Inc. ALGS · Entity 7352 | GrantStock Option (Right to Buy) · Derivative | 308,940 | $0.00 Strike: $1.13 | $0.00 |
DisclosureSEC source: 0001610717-24-000123 · form4.xml · derivative · entry 1 Calhoun Lesley Ann · CIK 0001730866 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 308,940 Underlying: Common Stock · 308,940 shares Expires 2034-03-01 F1 · derivative.exercise_date: 1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from March 1, 2024 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| February 28, 2024 Filed Feb 28, 2024 22:32 UTC | Aligos Therapeutics, Inc. ALGS · Entity 7352 | GrantStock Option (Right to Buy) · Derivative | 18,750 | $0.00 Strike: $0.96 | $0.00 |
DisclosureSEC source: 0001610717-24-000099 · form4.xml · derivative · entry 6 Calhoun Lesley Ann · CIK 0001730866 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,750 Underlying: Common Stock · 18,750 shares Expires 2032-02-04 F3 · price: On February 27, 2024, the issuer canceled, pursuant to the issuer's option exchange program, an option for 26,250 of the issuer's shares granted to the reporting person on February 4, 2022. In exchange, on February 28, 2024, the reporting person received a replacement option, for 18,750 shares, having an exercise price of $0.96 per share. F4 · derivative.exercise_date: The shares subject to the option will vest and become exercisable on the one year anniversary of the date of grant, subject to the reporting person's continued service with the issuer through such one year anniversary. Read SEC document |
| February 28, 2024 Filed Feb 28, 2024 22:32 UTC | Aligos Therapeutics, Inc. ALGS · Entity 7352 | GrantStock Option (Right to Buy) · Derivative | 74,998 | $0.00 Strike: $0.96 | $0.00 |
DisclosureSEC source: 0001610717-24-000099 · form4.xml · derivative · entry 5 Calhoun Lesley Ann · CIK 0001730866 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,998 Underlying: Common Stock · 74,998 shares Expires 2032-02-04 F2 · price: On February 27, 2024, the issuer canceled, pursuant to the issuer's option exchange program, an option for 105,000 of the issuer's shares granted to the reporting person on February 4, 2022. In exchange, on February 28, 2024, the reporting person received a replacement option, for 74,998 shares, having an exercise price of $0.96 per share. F5 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 75% of the total number of shares subject to the option on the one year anniversary of the date of the grant and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the reporting person's continued service with the issuer on each such vesting date. Read SEC document |
| February 28, 2024 Filed Feb 28, 2024 22:32 UTC | Aligos Therapeutics, Inc. ALGS · Entity 7352 | GrantStock Option (Right to Buy) · Derivative | 51,833 | $0.00 Strike: $0.96 | $0.00 |
DisclosureSEC source: 0001610717-24-000099 · form4.xml · derivative · entry 4 Calhoun Lesley Ann · CIK 0001730866 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,833 Underlying: Common Stock · 51,833 shares Expires 2030-12-01 F1 · price: On February 27, 2024, the issuer canceled, pursuant to the issuer's option exchange program, an option for 176,237 of the issuer's shares granted to the reporting person on December 1, 2020. In exchange, on February 28, 2024, the reporting person received a replacement option, for 51,833 shares, having an exercise price of $0.96 per share. F4 · derivative.exercise_date: The shares subject to the option will vest and become exercisable on the one year anniversary of the date of grant, subject to the reporting person's continued service with the issuer through such one year anniversary. Read SEC document |
| February 27, 2024 Filed Feb 28, 2024 22:32 UTC | Aligos Therapeutics, Inc. ALGS · Entity 7352 | Disposition to issuerStock Option (Right to Buy) · Derivative | 26,250 | $0.00 Strike: $3.06 | $0.00 |
DisclosureSEC source: 0001610717-24-000099 · form4.xml · derivative · entry 3 Calhoun Lesley Ann · CIK 0001730866 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 26,250 shares Expires 2032-02-04 F3 · price: On February 27, 2024, the issuer canceled, pursuant to the issuer's option exchange program, an option for 26,250 of the issuer's shares granted to the reporting person on February 4, 2022. In exchange, on February 28, 2024, the reporting person received a replacement option, for 18,750 shares, having an exercise price of $0.96 per share. Read SEC document |
| February 27, 2024 Filed Feb 28, 2024 22:32 UTC | Aligos Therapeutics, Inc. ALGS · Entity 7352 | Disposition to issuerStock Option (Right to Buy) · Derivative | 105,000 | $0.00 Strike: $3.06 | $0.00 |
DisclosureSEC source: 0001610717-24-000099 · form4.xml · derivative · entry 2 Calhoun Lesley Ann · CIK 0001730866 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 105,000 shares Expires 2032-02-04 F2 · price: On February 27, 2024, the issuer canceled, pursuant to the issuer's option exchange program, an option for 105,000 of the issuer's shares granted to the reporting person on February 4, 2022. In exchange, on February 28, 2024, the reporting person received a replacement option, for 74,998 shares, having an exercise price of $0.96 per share. Read SEC document |
| February 27, 2024 Filed Feb 28, 2024 22:32 UTC | Aligos Therapeutics, Inc. ALGS · Entity 7352 | Disposition to issuerStock Option (Right to Buy) · Derivative | 176,237 | $0.00 Strike: $16.18 | $0.00 |
DisclosureSEC source: 0001610717-24-000099 · form4.xml · derivative · entry 1 Calhoun Lesley Ann · CIK 0001730866 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 176,237 shares Expires 2030-12-01 F1 · price: On February 27, 2024, the issuer canceled, pursuant to the issuer's option exchange program, an option for 176,237 of the issuer's shares granted to the reporting person on December 1, 2020. In exchange, on February 28, 2024, the reporting person received a replacement option, for 51,833 shares, having an exercise price of $0.96 per share. Read SEC document |
| September 08, 2023 Filed Sep 12, 2023 20:07 UTC | Aligos Therapeutics, Inc. ALGS · Entity 7352 | GrantStock Option (Right to Buy) · Derivative | 48,000 | $0.00 Strike: $0.84 | $0.00 |
DisclosureSEC source: 0001610717-23-000276 · form4.xml · derivative · entry 1 Calhoun Lesley Ann · CIK 0001730866 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,000 Underlying: Common Stock · 48,000 shares Expires 2033-09-08 F1 · derivative.exercise_date: 1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from July 20, 2023 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| June 06, 2023 Filed Jun 9, 2023 01:39 UTC | Tango Therapeutics, Inc. TNGX · Entity 1497 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $3.55 | $0.00 |
DisclosureSEC source: 0000899243-23-015019 · doc4.xml · derivative · entry 2 Calhoun Lesley Ann · CIK 0001730866 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2033-06-06 F2 · derivative.exercise_date: This option shall vest and become exercisable in 12 substantially equal monthly installments over a period of one year beginning on July 6, 2023, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date. Read SEC document |
| June 06, 2023 Filed Jun 9, 2023 01:39 UTC | Tango Therapeutics, Inc. TNGX · Entity 1497 | GrantCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-015019 · doc4.xml · nonDerivative · entry 1 Calhoun Lesley Ann · CIK 0001730866 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 F1 · shares: These shares are represented by restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest in its entirety on the earlier of: (i) June 6, 2024 and (ii) the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date. Read SEC document |
| March 15, 2023 Filed Mar 17, 2023 20:11 UTC | Aligos Therapeutics, Inc. ALGS · Entity 7352 | GrantStock Option (Right to Buy) · Derivative | 78,750 | $0.00 Strike: $1.34 | $0.00 |
DisclosureSEC source: 0001567619-23-005255 · doc1.xml · derivative · entry 1 Calhoun Lesley Ann · CIK 0001730866 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,750 Underlying: Common Stock · 78,750 shares Expires 2033-03-15 F1 · derivative.exercise_date: 1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from March 15, 2023 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| July 07, 2022 Filed Jul 11, 2022 20:14 UTC | Aligos Therapeutics, Inc. ALGS · Entity 7352 | GrantStock Option (Right to Buy) · Derivative | 52,500 | $0.00 Strike: $1.41 | $0.00 |
DisclosureSEC source: 0001567619-22-013868 · doc1.xml · derivative · entry 1 Calhoun Lesley Ann · CIK 0001730866 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,500 Underlying: Common Stock · 52,500 shares Expires 2032-07-07 F1 · derivative.exercise_date: 1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from July 7, 2022 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| June 08, 2022 Filed Jun 28, 2022 20:28 UTC | Tango Therapeutics, Inc. TNGX · Entity 1497 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $5.90 | $0.00 |
DisclosureSEC source: 0000899243-22-024399 · doc4.xml · derivative · entry 1 Calhoun Lesley Ann · CIK 0001730866 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2032-06-08 F1 · derivative.exercise_date: This option shall vest and become exercisable in 12 substantially equal monthly installments over a period of one year from June 8, 2022, subject to the Reporting Person's continuous service on the board of directors as of each such vesting date. Read SEC document |
| February 04, 2022 Filed Feb 8, 2022 21:08 UTC | Aligos Therapeutics, Inc. ALGS · Entity 7352 | GrantStock Option (Right to Buy) · Derivative | 26,250 | $0.00 Strike: $3.06 | $0.00 |
DisclosureSEC source: 0001567619-22-002891 · doc1.xml · derivative · entry 2 Calhoun Lesley Ann · CIK 0001730866 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,250 Underlying: Common Stock · 26,250 shares Expires 2032-02-04 F2 · derivative.exercise_date: 100% of the shares subject to the Option will be fully vested and exercisable as of the third anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through such vesting date. Read SEC document |
| February 04, 2022 Filed Feb 8, 2022 21:08 UTC | Aligos Therapeutics, Inc. ALGS · Entity 7352 | GrantStock Option (Right to Buy) · Derivative | 105,000 | $0.00 Strike: $3.06 | $0.00 |
DisclosureSEC source: 0001567619-22-002891 · doc1.xml · derivative · entry 1 Calhoun Lesley Ann · CIK 0001730866 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,000 Underlying: Common Stock · 105,000 shares Expires 2032-02-04 F1 · derivative.exercise_date: 1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from February 4, 2022 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| December 01, 2020 Filed Dec 4, 2020 01:04 UTC | Aligos Therapeutics, Inc. ALGS · Entity 7352 | GrantStock Option (Right to Buy) · Derivative | 176,237 | $0.00 Strike: $16.18 | $0.00 |
DisclosureSEC source: 0001567619-20-020624 · doc1.xml · derivative · entry 1 Calhoun Lesley Ann · CIK 0001730866 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 176,237 Underlying: Common Stock · 176,237 shares Expires 2030-12-01 F1 · derivative.exercise_date: Subject to the Reporting Person's continued service to the Company through her one year anniversary as an employee with the issuer (which is May 31, 2021), 1/48th of the total number of shares subject to the option vest in forty-eight (48) successive and equal monthly installments measured from December 1, 2020 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| May 26, 2020 Filed May 28, 2020 16:05 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,700 | $0.00 Strike: $29.75 | $0.00 |
DisclosureSEC source: 0000899243-20-014410 · doc4.xml · derivative · entry 3 Calhoun Lesley Ann · CIK 0001730866 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 900 Underlying: Common Stock · 2,700 shares Expires 2027-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The Stock Option becomes exercisable in sixteen equal quarterly installments after March 1, 2017 until fully vested on March 1, 2021, subject to the Reporting Person's continuous service with the Issuer. The Stock Option is subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. Read SEC document |
| May 26, 2020 Filed May 28, 2020 16:05 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | SaleCommon Stock | 2,700 | $70.10 | $189,270.00 |
DisclosureSEC source: 0000899243-20-014410 · doc4.xml · nonDerivative · entry 2 Calhoun Lesley Ann · CIK 0001730866 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 154 Read SEC document |
| May 26, 2020 Filed May 28, 2020 16:05 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Exercise / conversionCommon Stock | 2,700 | $29.75 | $80,325.00 |
DisclosureSEC source: 0000899243-20-014410 · doc4.xml · nonDerivative · entry 1 Calhoun Lesley Ann · CIK 0001730866 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,854 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 18, 2020 Filed May 20, 2020 16:07 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Exercise / conversionStock Option (Right to Buy) · Derivative | 23,330 | $0.00 Strike: $22.00 | $0.00 |
DisclosureSEC source: 0000899243-20-013683 · doc4.xml · derivative · entry 3 Calhoun Lesley Ann · CIK 0001730866 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,875 Underlying: Common Stock · 23,330 shares Expires 2026-08-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The Stock Option becomes exercisable with respect to 1/4th of the underlying shares on August 15, 2017 and with respect to an additional 1/12th of the underlying shares each quarter thereafter until fully vested on August 15, 2020, subject to the Reporting Person's continuous service with the Issuer. The Stock Option is subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. Read SEC document |
| May 18, 2020 Filed May 20, 2020 16:07 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | SaleCommon Stock | 23,330 | $74.67 | $1,742,051.10 |
DisclosureSEC source: 0000899243-20-013683 · doc4.xml · nonDerivative · entry 2 Calhoun Lesley Ann · CIK 0001730866 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 154 Read SEC document |
| May 18, 2020 Filed May 20, 2020 16:07 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Exercise / conversionCommon Stock | 23,330 | $22.00 | $513,260.00 |
DisclosureSEC source: 0000899243-20-013683 · doc4.xml · nonDerivative · entry 1 Calhoun Lesley Ann · CIK 0001730866 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,484 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 12, 2020 Filed May 13, 2020 18:08 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | SaleCommon Stock | 2,992 | $78.38 | $234,512.36 |
DisclosureSEC source: 0000899243-20-013018 · doc4.xml · nonDerivative · entry 2 Calhoun Lesley Ann · CIK 0001730866 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 154 F1 · price: Represents the weighted average sale price of the shares sold ranging from $78.34 to $78.41 per share, inclusive. The Reporting Person will provide, upon request by the Issuer, a security holder of the Issuer, or the staff of the Securities and Exchange Commission, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 11, 2020 Filed May 13, 2020 18:08 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | SaleCommon Stock | 381 | $77.05 | $29,355.75 |
DisclosureSEC source: 0000899243-20-013018 · doc4.xml · nonDerivative · entry 1 Calhoun Lesley Ann · CIK 0001730866 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,146 Read SEC document |
| March 01, 2020 Filed Mar 4, 2020 20:48 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Exercise / conversionRestricted Stock Units · Derivative | 300 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-007087 · doc4.xml · derivative · entry 3 Calhoun Lesley Ann · CIK 0001730866 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 600 Underlying: Common Stock · 300 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F3 · derivative.exercise_date: The RSUs vest in eight semiannual installments after March 1, 2017 until fully vested on March 1, 2021, subject to the Reporting Person's continuous service with the Issuer. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. F3 · derivative.expiration_date: The RSUs vest in eight semiannual installments after March 1, 2017 until fully vested on March 1, 2021, subject to the Reporting Person's continuous service with the Issuer. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. Read SEC document |
| March 01, 2020 Filed Mar 4, 2020 20:48 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Tax withholdingCommon Stock | 104 | $63.96 | $6,651.84 |
DisclosureSEC source: 0000899243-20-007087 · doc4.xml · nonDerivative · entry 2 Calhoun Lesley Ann · CIK 0001730866 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,527 F2 · shares: Represents number of shares of Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligations in connection with the vesting of 300 shares of Common Stock underlying the Reporting Person's RSUs. Read SEC document |
| March 01, 2020 Filed Mar 4, 2020 20:48 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Exercise / conversionCommon Stock | 300 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-007087 · doc4.xml · nonDerivative · entry 1 Calhoun Lesley Ann · CIK 0001730866 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,631 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| February 03, 2020 Filed Feb 4, 2020 20:52 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | GrantStock Option (Right to Buy) · Derivative | 14,610 | $0.00 Strike: $65.82 | $0.00 |
DisclosureSEC source: 0000899243-20-003048 · doc4.xml · derivative · entry 7 Calhoun Lesley Ann · CIK 0001730866 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,610 Underlying: Common Stock · 14,610 shares Expires 2030-02-02 F7 · derivative.exercise_date: The shares of Common Stock underlying the option vest in 16 equal quarterly installments over 4 years from February 1, 2020, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The options are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. Read SEC document |
| February 03, 2020 Filed Feb 4, 2020 20:52 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | GrantRestricted Stock Units · Derivative | 9,160 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-003048 · doc4.xml · derivative · entry 6 Calhoun Lesley Ann · CIK 0001730866 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,160 Underlying: Common Stock · 9,160 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. F6 · derivative.exercise_date: The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2020, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. F6 · derivative.expiration_date: The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2020, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. Read SEC document |
| February 01, 2020 Filed Feb 4, 2020 20:52 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Exercise / conversionRestricted Stock Units · Derivative | 2,313 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-003048 · doc4.xml · derivative · entry 5 Calhoun Lesley Ann · CIK 0001730866 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,875 Underlying: Common Stock · 2,313 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. F5 · derivative.exercise_date: The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2019, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. F5 · derivative.expiration_date: The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2019, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. Read SEC document |
| February 01, 2020 Filed Feb 4, 2020 20:52 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Exercise / conversionRestricted Stock Units · Derivative | 750 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-003048 · doc4.xml · derivative · entry 4 Calhoun Lesley Ann · CIK 0001730866 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 Underlying: Common Stock · 750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. F4 · derivative.exercise_date: The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2018, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. F4 · derivative.expiration_date: The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2018, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. Read SEC document |
| February 01, 2020 Filed Feb 4, 2020 20:52 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Tax withholdingCommon Stock | 1,154 | $65.26 | $75,310.04 |
DisclosureSEC source: 0000899243-20-003048 · doc4.xml · nonDerivative · entry 3 Calhoun Lesley Ann · CIK 0001730866 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,331 F3 · shares: Represents number of shares of Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligations in connection with the vesting of 3,063 shares of Common Stock underlying the Reporting Person's RSUs. Read SEC document |
| February 01, 2020 Filed Feb 4, 2020 20:52 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Exercise / conversionCommon Stock | 3,063 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-003048 · doc4.xml · nonDerivative · entry 2 Calhoun Lesley Ann · CIK 0001730866 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,485 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. Read SEC document |
| January 31, 2020 Filed Feb 4, 2020 20:52 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | GrantCommon Stock | 535 | $36.68 | $19,623.80 |
DisclosureSEC source: 0000899243-20-003048 · doc4.xml · nonDerivative · entry 1 Calhoun Lesley Ann · CIK 0001730866 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,422 F1 · shares: Shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| September 11, 2019 Filed Sep 13, 2019 16:45 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | SaleCommon Stock | 2,765 | $54.36 | $150,296.28 |
DisclosureSEC source: 0000899243-19-023567 · doc4.xml · nonDerivative · entry 1 Calhoun Lesley Ann · CIK 0001730866 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 887 F1 · price: Represents the weighted average sale price of the shares sold ranging from $54.32 to $54.36 per share, inclusive. The Reporting Person will provide, upon request by the Issuer, a security holder of the Issuer, or the staff of the Securities and Exchange Commission, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 01, 2019 Filed Sep 4, 2019 16:29 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Exercise / conversionRestricted Stock Units · Derivative | 300 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-022728 · doc4.xml · derivative · entry 3 Calhoun Lesley Ann · CIK 0001730866 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 900 Underlying: Common Stock · 300 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F3 · derivative.exercise_date: The RSUs vest in eight semiannual installments after March 1, 2017 until fully vested on March 1, 2021, subject to the Reporting Person's continuous service with the Issuer. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. F3 · derivative.expiration_date: The RSUs vest in eight semiannual installments after March 1, 2017 until fully vested on March 1, 2021, subject to the Reporting Person's continuous service with the Issuer. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. Read SEC document |
| September 01, 2019 Filed Sep 4, 2019 16:29 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Tax withholdingCommon Stock | 104 | $45.98 | $4,781.92 |
DisclosureSEC source: 0000899243-19-022728 · doc4.xml · nonDerivative · entry 2 Calhoun Lesley Ann · CIK 0001730866 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,652 F2 · shares: Represents number of shares of Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligations in connection with the vesting of 300 shares of Common Stock underlying the Reporting Person's RSUs. Read SEC document |
| September 01, 2019 Filed Sep 4, 2019 16:29 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Exercise / conversionCommon Stock | 300 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-022728 · doc4.xml · nonDerivative · entry 1 Calhoun Lesley Ann · CIK 0001730866 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,756 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| August 01, 2019 Filed Aug 5, 2019 17:06 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Exercise / conversionRestricted Stock Units · Derivative | 2,312 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-021013 · doc4.xml · derivative · entry 5 Calhoun Lesley Ann · CIK 0001730866 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,188 Underlying: Common Stock · 2,312 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. F5 · derivative.exercise_date: The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2019, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. F5 · derivative.expiration_date: The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2019, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.